Protalix BioTherapeutics, Inc. is rated a Buy due to robust FY26 revenue guidance of $78–83 million. Learn more about PLX ...
SkyWater Technology hits record FY2025 revenue, but margins, cash flow, and leverage raise risk. Click here to read my latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results